AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- Details
- Category: AstraZeneca
AstraZeneca today announced it intends to seek reconsideration or reversal of a verdict in the Montgomery County Circuit Court awarding $40 million in compensatory damages and $175 million in punitive damages for alleged false and misleading reporting of prices for drugs reimbursed by the Alabama State Medicaid Agency in the US.
Shire plc accelerating new product sales drive revenue growth of 36%
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 â a year which has seen significant growth in launched products.
Financial Highlights, 2007 Full Year:
Financial Highlights, 2007 Full Year:
New price reductions for GSK antiretrovirals in the world's poorest countries
- Details
- Category: GlaxoSmithKline
GSK today announced significant new price reductions for its HIV medicines offered on a not-for-profit basis to the world's poorest countries. This reduction is the fifth time the company has made a price reduction as part of its pioneering preferential pricing policy originally introduced in 1997.
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
- Details
- Category: Financial
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, for the fourth quarter of 2007 compared to a net loss of $20.7 million, or $0.47 per share, in the same period in the prior year.
Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that a Phase III trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the study would not meet its primary endpoint of improved overall survival.
Trasylol® - One Thousand Lives A Month
- Details
- Category: Product
A renowned researcher estimates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago. Scott Pelley reports.
CBSNews.com
CBSNews.com
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
- Details
- Category: Financial
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to US$44 million, comprising an upfront fee and development milestones, plus royalties on future sales.
More Pharma News ...
- FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
- Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin)
- Pharmion and MethylGene Announce U.S. Orphan Drug Designation
- AstraZeneca and Nomura Phase4 Ventures Announce Creation of New Company "Albireo"
- The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results
- Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
- First Head to Head Study Comparing CRESTOR and LIPITOR®